Tags
- 13 Years
- 20 Years
- 24 Weeks
- 3
- 3 Andromedae
- 4
- 4 Andromedae
- 50 Years
- 5A
- 9
- A
- AbbVie Inc.
- Abdominal
- Abdominal pain
- Accelerated
- Accelerated approval
- ACHES
- Achievement
- Active immunization
- Acute
- Adeno-associated virus
- Administration
- Adult
- Adverse
- Adverse effect
- Adverse reactions
- Agent
- Ages
- Agriculture in the United States
- Air
- Alkaline
- Alkaline phosphatase
- ALT
- Alway, Newport
- Ambulatory
- Ampoule
- An
- And 1
- Andromeda XXII
- Anemia
- Anne Anderson
- Anti-inflammatory
- Anti-inflammatory effects
- Approval
- Approved
- Approximately
- Arthralgia
- Arthritis
- AST
- At Home
- At Risk
- Avoidance
- Back pain
- Bacteremia
- Bacteria
- Bacterial pneumonia
- Based on
- Baseline
- Benefit
- Binding
- Bladder
- Block
- Blocking
- Blood
- Blood cell
- Blood Cells
- Blood in stool
- Blood pressure
- Bloodstream
- Blood transfusion
- Bloody
- Body
- Boxed
- Boxed warning
- Brain
- Breakthrough
- Breath
- Breathing
- Bronchodilator
- Bronchospasm
- Bruise
- BTH
- C5
- Cancer
- Cardiac muscle
- Cardiovascular disease
- Carries
- Cause
- Causes
- Cell
- Cells
- Childhood
- Chronic
- Chronic obstructive pulmonary disease
- Classified
- Clinical
- Clinical endpoint
- Clinical trial
- Clinical Trials
- Colitis
- Colón
- Combine
- Commodore
- Common side effects
- Comparable
- Complement
- Complement component 5
- Conjugate
- Conjugate vaccine
- Consecutive
- Containment
- Continued
- Copd symptoms
- Cord
- Corporation
- Covering
- Coverings
- COVID-19
- Crohn's disease
- Damage
- Data
- Day 1
- Death
- Delivering
- Delta Andromedae
- Demonstration
- Destroyed
- Digestive
- Disease
- DMD
- Dmd gene
- Doctor of Pharmacy
- Dosage
- Dose
- Dosing
- Drug
- Drugs.com
- Dual
- Duchenne
- Duchenne muscular dystrophy
- Durable
- Duration
- Dystrophin
- Dystrophin protein
- Dystrophy
- Early childhood
- Eculizumab
- Effect
- Efficacy
- Efficacy endpoint
- Efficacy endpoints
- Eight
- Encode
- Endpoint
- Endpoints
- Enhance
- Enzyme
- Erythropoiesis-stimulating agent
- Every
- Exon
- Expansion
- Expulsion
- Fatigue
- FDA
- Feces
- Fever
- Following
- Food
- Food and Drug Administration
- Four
- Functional
- Function test
- Gastrointestinal tract
- Genentech
- Gene therapy
- Genetic
- Genetic disorder
- Geron Corporation
- Grant
- Grants
- Headache
- Health
- Heart
- Hemoglobin
- Hemoglobinuria
- Hemolysis
- Horizontal gene transfer
- Hour
- Hours
- Hypertension
- If
- IL-23
- Immune
- Immune disorder
- Immune system
- Immunization
- Incidence
- Include
- Includes
- Independence
- Induction
- Infection
- Inflammation
- Inflammatory
- Inflammatory bowel disease
- Infusion
- Inhalation
- Inhaler
- Inhibitor
- Initial
- Injection
- Injection site
- Injection site reaction
- Injector
- Injury
- Instruction
- Instructions
- Intact
- Interleukin 23
- In the Bone
- Intramuscular injection
- Intravenous therapy
- Invasive
- Invasive disease
- Keep
- Kidney
- Kill
- Kills
- Label
- Last updated
- Launch
- LB
- Leigh Ann
- Lethality
- Lining
- Liver
- Liver function tests
- Liver injury
- Loading
- Loading dose
- Loss
- Maintenance
- Maintenance, repair and operations
- Male
- Malignant
- Manufacturing
- Mature
- Maximal
- MDS
- Mechanism
- Mechanism of action
- Medicine
- Meningitis
- Meningococcal disease
- Merck
- Minimally invasive procedures
- Molecule
- Most
- Much
- Muscle
- Muscles
- MUSCULAR
- Muscular dystrophy
- Mutation
- Myalgia
- Myelodysplastic syndrome
- Myocarditis
- Myocyte
- Myositis
- Nausea
- Nebulizer
- Need
- Neisseria
- Neisseria meningitidis
- Neutropenia
- New
- Nocturnal
- Nonsteroidal
- Nonsteroidal anti-inflammatory drug
- Novel
- Obstructive
- Older
- Oligonucleotide
- One Second
- One Year
- Only
- Option
- Oral inhalation
- Over
- Pain
- Paradox
- Paroxysmal attack
- Paroxysmal nocturnal hemoglobinuria
- Partial
- Partial thromboplastin time
- Patient
- Pediatric patient
- Pediatrics
- Pharma
- Pharmaceutical drug
- Pharmacovigilance
- Phase
- Phase 3
- Phase III
- -phosphatase
- Phosphodiesterase
- Phosphodiesterase 3
- Phosphodiesterase 4
- Phosphodiesterase-4 inhibitor
- Placebo
- Placebo-controlled study
- Plaque
- Platelet
- Platelets
- Pneumococcal conjugate vaccine
- Pneumococcal pneumonia
- Pneumococcal vaccine
- Pneumonia
- PNH
- Precaution
- Precautions
- Prefilled syringe
- Premature
- Pressure
- Prevention
- Primary
- Product
- Profile
- Progenitor
- Progenitor cell
- Progressive
- Prolonged
- Protein
- Psoriasis
- Psoriatic arthritis
- Psychiatry
- Pulmonary function testing
- Putting
- Quarter
- Reaction
- Recognized
- Recommended
- Red blood
- Red blood cell
- Remission
- Rems
- Rescue
- Rescue inhaler
- Respiratory disease
- Responsibility
- Result
- Risk
- Roundup
- R rating
- Safety
- Sarepta
- Sarepta Therapeutics
- Second
- Secondary
- Serotype
- Severity
- Shortened
- Shortness
- Shortness of breath
- Side Effects
- Single
- Skeleton
- Skin
- Small molecule
- Some
- Spinal cord
- SPINE
- Spirometry
- Stabilization
- Start
- Starter
- St Clears
- Stem
- Stool
- Streptococcus
- Streptococcus pneumoniae
- Studie
- Subcutaneous
- Subcutaneous injection
- Sudden
- Suicidal ideation
- Sustain
- Symptom
- Symptoms
- Syndrome
- Syringe
- Telomerase
- The age
- The body
- The brain
- The Covering
- The first
- Then
- Therapy
- Third
- Thrombocytopenia
- Thromboplastin
- Thrombus
- To Heart
- Tract
- Traditional
- Training
- Transfer
- Transfusion
- Treat
- Trial
- Trials
- Twice
- Ulcer
- Ulcerative colitis
- Underlying
- Under the Skin
- Urgency
- Urinary tract infection
- Vaccine
- Verification
- Verona Pharma
- Via
- Visible
- Vomiting
- Vomiting and nausea
- Warning
- Weakness
- Weekly
- Weigh
- White Blood Cells
- Who
- Year Eight